Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol's HCV Bump Catalyzes Strong Quarter, But Not Expected To Last

Executive Summary

Daklinza has been part of the standard of care in genotype 3 HCV, but the launch of Gilead's Epclusa and an EU ramp-up of Merck's Zepatier are expected to erode that over time.


Related Content

Bristol Stresses Cost Control Despite Strong Earnings Quarter
Will Real-World Data Sway Course Of Novel Anticoagulant Market?
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
NICE Reverses Stance On BMS' HCV Pill Daklinza
Success Of Bristol’s Daklinza In Europe May Be Tied To Fate Of Sovaldi


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts